New revelations from an investment bank show the danger private companies pose to our health

investment bank Goldman Sachs on hepatitis C

A report by analysts at the investment bank Goldman Sachs questions if curing diseases is a “sustainable business model”. It says highly effective “one shot cures” might not be the best way to sustain “cash flow”.

The findings reveal the potential risks of private company involvement in healthcare.

Curing disease is bad for business

A recent Goldman Sachs report titled The Genome Revolution, advised clients what potential profit they can make by developing different treatments. The authors state that those which result in a ‘stable pool of patients’ are a better way to secure long-term profits. Analyst Salveen Richter wrote:

The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.

The report points to the example of Gilead Sciences, which has produced treatments for Hepatitis C. The company claims its treatments have cure rates of more than 90%. In 2015, the company made $12.5bn but profits fell sharply as people were cured, and no longer in need of treatment. Goldman Sachs estimates that Gilead Sciences will make under $4bn in 2018 from these treatments.

In light of this trend, GlaxoSmithKline has been selling off gene therapies that are able to cure rare diseases.

The marketization of healthcare

There are further examples of the detrimental effect of the market on healthcare. Preventive medicine, for example, is less profitable than treating the symptoms of a health problem over a lifetime. As a result, in the US the health system invests more in heart surgery than preventing heart disease by improving patients’ diets and fitness.

Read on...

Brian Fisher, a GP and former chair of the Socialist Health Association, argues [paywall] that the marketization of healthcare is risky. Referring to the privatisation of the NHS, he says:

Marketisation means a system where relationships and behaviours are driven by competition and profit.

Health is not a commodity, patients are not customers, and choices about our care are not a form of shopping.


The Goldman Sachs report, however, doesn’t advise companies not to develop ‘one shot cures’. It makes the observation that this may not be profitable in the long-term. And authors recommend that companies be innovative and diversify their treatments to ensure that their bottom line doesn’t suffer.

But the danger is that, if a company prioritises profits over people, then overall, fewer lives will be saved.

Get Involved!

– Read more articles from The Canary‘s Health section.

Join us, so we can keep bringing you the news that matters.

Featured image via Wikimedia

This article was updated on 16 April 2017 to reflect the fact that Brian Fisher is the former chair of the Socialist Health Association. 

We need your help to keep speaking the truth

Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.

Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.

We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.

In return, you get:

* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop

Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.

With your help we can continue:

* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do

We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?

The Canary Support us

Comments are closed